SynthesisBMC neurology2026
Efficacy and safety of Tirofiban following intravenous thrombolysis: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe risk of re-occlusion and inadequate reperfusion limits the efficacy of intravenous thrombolysis (IVT) within 4.5 h for acute ischemic stroke (AIS). Tirofiban, a glycoprotein IIb/IIIa inhibitor, has been studied as an adjunctive treatment for patients with acute coronary syndrome. This meta-analysis evaluates existing evidence on the effectiveness and safety of Tirofiban following thrombolysis in patients with acute ischemic stroke.
methodsPubMed, ScienceDirect, and The Cochrane Library were searched for RCTs published between 2011 and 2025. All studies included acute ischemic stroke patients, aged ≥ 18 years, NIHSS > 4, who received IV thrombolysis before Tirofiban administration. Endpoints included modified Rankin scale (mRS) score, symptomatic intracranial hemorrhage (SICH), risk of systemic bleeding, and mortality. The quality of the studies was assessed using the ROB2 tool, and risk ratios were calculated and analyzed. The protocol was registered on PROSPERO (CRD420251106033).
resultsFive trials met the inclusion criteria. Two trials had a low risk of bias, one had some concerns, and two had a high risk of bias. Results showed a significant improvement in mRS score with IVT plus Tirofiban (RR 1.32; 95% CI 1.07–1.62; p = 0.010), while also showing an increase in SICH with IVT plus Tirofiban; however, the results were not significant (RR 1.86; 95% CI 0.18–19.24; p = 0.60). No difference was observed in mortality between the two groups (RR 1.06; 95% CI 0.56–2.04; p = 0.85).
conclusionIVT plus Tirofiban significantly improves functional outcomes without increasing mortality despite the risk of SICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.